A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database

Tirzepatide is a novel drug for the treatment of type 2 diabetes mellitus and chronic weight management, and there is an urgent need to explore its safety profile. The FDA Adverse Event Reporting System (FAERS) database provides a reliable pathway for adverse event (AE) disproportionality analysis....

全面介紹

書目詳細資料

Principais autores:	Jie Li, Jun Xie, Yi Han, Wei Zhang, Yilei Wang, Zhitao Jiang
格式:	Artigo
語言:	Inglês
出版:	The Japan Endocrine Society 2025-03-01
叢編:	Endocrine Journal
主題:	tirzepatide gip/glp-1 ra disproportionality analysis fda adverse event reporting system (faers) adverse drug event
在線閱讀:	https://www.jstage.jst.go.jp/article/endocrj/72/3/72_EJ24-0286/_html/-char/en
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!